These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26913923)

  • 1. Assessment of Primary Cancer Incidence in Growth Hormone-Treated Children: Comparison of a Multinational Prospective Observational Study with Population Databases.
    Child CJ; Zimmermann AG; Jia N; Robison LL; Brämswig JH; Blum WF
    Horm Res Paediatr; 2016; 85(3):198-206. PubMed ID: 26913923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS.
    Woodmansee WW; Zimmermann AG; Child CJ; Rong Q; Erfurth EM; Beck-Peccoz P; Blum WF; Robison LL;
    Eur J Endocrinol; 2013 Apr; 168(4):565-73. PubMed ID: 23359434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program.
    Child CJ; Zimmermann AG; Chrousos GP; Cummings E; Deal CL; Hasegawa T; Jia N; Lawrence S; Linglart A; Loche S; Maghnie M; Pérez Sánchez J; Polak M; Predieri B; Richter-Unruh A; Rosenfeld RG; Yeste D; Yorifuji T; Blum WF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):379-389. PubMed ID: 30219920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.
    Krzyzanowska-Mittermayer K; Mattsson AF; Maiter D; Feldt-Rasmussen U; Camacho-Hübner C; Luger A; Abs R
    J Clin Endocrinol Metab; 2018 Feb; 103(2):523-531. PubMed ID: 29228199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
    Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
    Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program.
    Child CJ; Zimmermann AG; Scott RS; Cutler GB; Battelino T; Blum WF;
    J Clin Endocrinol Metab; 2011 Jun; 96(6):E1025-34. PubMed ID: 21490076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Meningioma in European Patients Treated With Growth Hormone in Childhood: Results From the SAGhE Cohort.
    Swerdlow AJ; Cooke R; Beckers D; Butler G; Carel JC; Cianfarani S; Clayton P; Coste J; Deodati A; Ecosse E; Hokken-Koelega ACS; Khan AJ; Kiess W; Kuehni CE; Flück CE; Pfaffle R; Sävendahl L; Sommer G; Thomas M; Tidblad A; Tollerfield S; Zandwijken GRJ
    J Clin Endocrinol Metab; 2019 Mar; 104(3):658-664. PubMed ID: 30137467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries.
    Olsen JH; Möller T; Anderson H; Langmark F; Sankila R; Tryggvadóttír L; Winther JF; Rechnitzer C; Jonmundsson G; Christensen J; Garwicz S
    J Natl Cancer Inst; 2009 Jun; 101(11):806-13. PubMed ID: 19470947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone improves short stature in children with Diamond-Blackfan anemia.
    Howell JC; Joshi SA; Hornung L; Khoury J; Harris RE; Rose SR
    Pediatr Blood Cancer; 2015 Mar; 62(3):402-8. PubMed ID: 25492299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Italian cancer figures, report 2012: Cancer in children and adolescents.
    ; ;
    Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second malignant neoplasms following childhood cancer: a study of a recent cohort (1987-2004) from the childhood cancer registry of the Rhône-Alpes region (ARCERRA) in France.
    Berger C; Trombert-Paviot B; Casagranda L; Mialou V; Frappaz D; Plantaz D; Collardeau-Frachon S; Freycon F
    Pediatr Hematol Oncol; 2011 Aug; 28(5):364-79. PubMed ID: 21736475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.
    Cutfield WS; Wilton P; Bennmarker H; Albertsson-Wikland K; Chatelain P; Ranke MB; Price DA
    Lancet; 2000 Feb; 355(9204):610-3. PubMed ID: 10696981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor.
    Ergun-Longmire B; Mertens AC; Mitby P; Qin J; Heller G; Shi W; Yasui Y; Robison LL; Sklar CA
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3494-8. PubMed ID: 16822820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study.
    Child CJ; Zimmermann AG; Woodmansee WW; Green DM; Li JJ; Jung H; Erfurth EM; Robison LL;
    Eur J Endocrinol; 2011 Aug; 165(2):217-23. PubMed ID: 21646285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database).
    Wilton P; Mattsson AF; Darendeliler F
    J Pediatr; 2010 Aug; 157(2):265-70. PubMed ID: 20400105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia.
    Leung W; Rose SR; Zhou Y; Hancock ML; Burstein S; Schriock EA; Lustig R; Danish RK; Evans WE; Hudson MM; Pui CH
    J Clin Oncol; 2002 Jul; 20(13):2959-64. PubMed ID: 12089225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries.
    Maule M; Scélo G; Pastore G; Brennan P; Hemminki K; Olsen JH; Tracey E; Pukkala E; Weiderpass E; Brewster DH; Tamaro S; Chia KS; Pompe-Kirn V; Kliewer EV; Tonita JM; Martos C; Jonasson JG; Merletti F; Boffetta P
    Int J Cancer; 2011 Oct; 129(8):1940-52. PubMed ID: 21520035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
    Schaapveld M; Aleman BM; van Eggermond AM; Janus CP; Krol AD; van der Maazen RW; Roesink J; Raemaekers JM; de Boer JP; Zijlstra JM; van Imhoff GW; Petersen EJ; Poortmans PM; Beijert M; Lybeert ML; Mulder I; Visser O; Louwman MW; Krul IM; Lugtenburg PJ; van Leeuwen FE
    N Engl J Med; 2015 Dec; 373(26):2499-511. PubMed ID: 26699166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH therapy and cancer risk in hypopituitarism: what we know from human studies.
    Pekic S; Popovic V
    Eur J Endocrinol; 2013 Nov; 169(5):R89-97. PubMed ID: 23935131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.